Michelle Dipp, MD PhD is a Co-Founder and Managing Partner of Biospring Partners. She has over a decade of private equity and venture capital expertise in life sciences. Her background in thought leadership and research have been cited over 1000 times on Google Scholar. She currently serves on the Board of Abzena and Kiniciti.
Prior to co-founding this new business, Michelle was a Managing Director at General Atlantic, a global growth equity firm based in New York. While at General Atlantic Michelle launched their first life sciences investment platform and served as a member of the life sciences investment committee. Michelle served as a Board Observer for Ginkgo BioWorks and as a board member for PathAI and Immunocore.
On November 10, 2021 Biospring Partners announced that it would be joining Welsh, Carson, Anderson & Stowe (WCAS) as an investor to back one of the “fastest growing therapeutic classes…represent[ing] the future of medicine over the next decade.”
A new $200 million fund from Accolade Partners will help invest in funds started by underrepresented groups including Biospring Partners. Learn why more capital is going to these funds that outperform the market.
Biospring Partners is pround to announce that they have appointed Drew Pearson as Head of Portfolio Management. The life science venture capital firm has added several industry leaders to its Advisory Board.
A conversation about Life Science investment trends with Michelle Dipp, MD PhD, Co-Founder and Managing Partner at Biospring Partners.